News

Stories

See all

Updates: Lilly's Global COVID-19 Response

View Story

To the Millions of Americans Who Rely on Lilly Insulin

View Story

Lilly Manufacturing Facility

COVID-19 Update on Insulin Affordability and Supply

View Story

In Bolivia, Life for a Child Helps a Youth Achieve His Dream

View Story

Lilly Scientist Meets Patient Helped by Cancer Discovery

View Story

Gemologist Benefits from Insulin Affordability Program

View Story


  2. 1

Press Releases

See all

Medical Professionals Across Merck & Co., Inc., Pfizer Inc., and Eli Lilly and Company Activate to Support Health Systems, First Responders and Patients Amid COVID-19 Pandemic

April 1, 2020

KENILWORTH, N.J. & NEW YORK & INDIANAPOLIS--(BUSINESS WIRE)--Apr. 1, 2020-- Merck & Co., Inc., (NYSE: MRK), Pfizer Inc. (NYSE: PFE), and Eli Lilly and Company (NYSE: LLY) today announced medical service volunteer programs to enable employees who are licensed medical professionals to aid in the fight against COVID-19 while maintaining their base pay.



Governor Holcomb and Mayor Hogsett announce coalition to flatten the COVID-19 curve across state, public invited to make commitment

April 1, 2020

INDIANAPOLIS, April 1, 2020 – Governor Eric J. Holcomb and Mayor Joe Hogsett – and a coalition of statewide business and community partners including Eli Lilly and Company – announced a social distancing campaign to help flatten the curve for COVID-19 in Indiana.



Lilly and Sitryx Announce Licensing and Research Collaboration to Discover and Develop New Immunometabolic Medicines

March 31, 2020

Tags |  Corporate

INDIANAPOLIS and OXFORD, England , March 31, 2020 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) today announced an exclusive global licensing and research collaboration with Sitryx, a biopharmaceutical company focused on regulating cell metabolism to develop disease-modifying therapeutics in



Lilly's Taltz® (ixekizumab) Receives U.S. FDA Approval for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis

March 30, 2020

Tags |  Product

-- Taltz is the first and only IL-17A antagonist approved to treat this population -- INDIANAPOLIS , March 30, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for